News & events Type your keyword Filter - Any -ArticleEventNews 19 September 2021 Shorter radiotherapy courses for prostate cancer are well tolerated long-term by patients A shorter course of radiotherapy, administered through fewer, higher intensity doses, is as well tolerated over five years as longer treatment courses for treating prostate cancer, long-term results of a clinical trial show. 19 September 2021 Drug combination shows promise in treatment-resistant advanced ovarian cancer A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients. 17 September 2021 Non-chemotherapy drug combination could extend time between treatments for ovarian cancer patients Results from a phase II randomised trial have shown that a combination of immunotherapy and a targeted therapy could extend time between treatments for some women with recurrent ovarian cancer. 29 August 2021 Advanced radiotherapy could safely deliver curative treatment, with 90% of patients still free from significant bowel and bladder side effects after two years Advanced radiotherapy technology can safely deliver curative treatment for prostate cancer patients in as few as five sessions, with only minimal side effects, according to new research from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. 22 August 2021 New BRCA-targeting drug could offer hope in treating advanced prostate cancer Talazoparib, a new precision drug, can keep cancer in check in some men with advanced prostate cancer who have run out of options, a phase II clinical trial shows. 26 July 2021 Scoring system predicts head and neck cancer patient response to immunotherapy A prognostic scoring system that is cheap, efficient and reliable can predict how patients with relapsed and/or metastatic head and neck cancer will respond to immunotherapy, new research has shown. 08 July 2021 New drug combination attacks prostate cancer on two fronts to keep men healthy for longer Men with particularly aggressive prostate cancers can be treated more effectively by combining an existing targeted medicine, abiraterone, with a new experimental drug to block two of cancer’s growth signals at once, a major new trial has shown. 30 June 2021 World’s first research centre for recurrent head and neck cancer launched To accelerate research and improve patient outcomes, the world’s first centre for recurrent head and neck cancer has been launched at The Royal Marsden NHS Foundation Trust thanks to Royal Marsden Cancer Charity funding. 25 June 2021 MRI images reconstructed by artificial intelligence could accelerate and better guide radiotherapy An artificial intelligence (AI) that reconstructs MRI images of moving tumours can do so in seconds, offering a significant improvement on current methods to optimise radiotherapy treatment in the clinic. 21 June 2021 Early promise for first targeted brain cancer treatment A new drug could become the first ever targeted brain cancer treatment, with encouraging early results from a phase 1 trial suggesting it could treat some patients with advanced disease. ‹ Previous 3 4 5 6 7 8 9 10 11 Next ›